GSK (GSK) RNS Announcements

Add to Alert list
Date Time Source Announcement
16 Jan 2017 06:08 PM
RNS
Director/PDMR Shareholding
16 Jan 2017 05:15 PM
RNS
Director/PDMR Shareholding
16 Jan 2017 05:04 PM
RNS
Director/PDMR Shareholding
16 Jan 2017 04:54 PM
RNS
Director/PDMR Shareholding
16 Jan 2017 04:01 PM
RNS
Director/PDMR Shareholding
16 Jan 2017 03:51 PM
RNS
Director/PDMR Shareholding
13 Jan 2017 04:40 PM
RNS
Director/PDMR Shareholding
13 Jan 2017 03:44 PM
RNS
Director/PDMR Shareholding
13 Jan 2017 02:29 PM
RNS
Director/PDMR Shareholding
12 Jan 2017 04:38 PM
RNS
Director/PDMR Shareholding
10 Jan 2017 04:51 PM
RNS
Director/PDMR Shareholding
03 Jan 2017 10:34 AM
RNS
Total Voting Rights
20 Dec 2016 02:03 PM
RNS
ViiV starts HIV prevention study with cabotegravir
20 Dec 2016 07:17 AM
RNS
Blocklisting Application
20 Dec 2016 07:00 AM
RNS
ViiV announce phase III results for 2-drug regimen
19 Dec 2016 03:19 PM
RNS
Directorate Change
19 Dec 2016 09:32 AM
RNS
Phase III study start for closed triple in asthma
16 Dec 2016 05:32 PM
RNS
Treasury Stock
16 Dec 2016 10:45 AM
RNS
Director/PDMR Shareholding
13 Dec 2016 09:11 AM
RNS
Audit Tender Conclusion
12 Dec 2016 03:56 PM
RNS
Director/PDMR Shareholding
02 Dec 2016 03:49 PM
RNS
Director/PDMR Shareholding
02 Dec 2016 02:19 PM
RNS
GSK files closed triple therapy for COPD in EU
02 Dec 2016 07:01 AM
RNS
Relvar Ellipta approved in Japan for COPD
01 Dec 2016 11:00 AM
RNS
Total Voting Rights
30 Nov 2016 04:52 PM
RNS
Director/PDMR Shareholding
25 Nov 2016 01:35 PM
RNS
EU submission of shingles candidate vaccine
24 Nov 2016 11:07 AM
RNS
Start of Phase III studies with daprodustat
23 Nov 2016 07:05 AM
RNS
Mepolizumab meets endpoints in phase 3 EGPA study
21 Nov 2016 07:02 AM
RNS
GSK files closed triple therapy for COPD in US
18 Nov 2016 02:40 PM
RNS
ViiV starts PhIII LA injectable treatment regimen
16 Nov 2016 04:04 PM
RNS
New phase III data of sirukumab for RA
10 Nov 2016 03:09 PM
RNS
Director/PDMR Shareholding
08 Nov 2016 05:04 PM
RNS
Block listing Interim Review
08 Nov 2016 05:01 PM
RNS
Director/PDMR Shareholding
04 Nov 2016 05:12 PM
RNS
Director/PDMR Shareholding
02 Nov 2016 04:49 PM
RNS
Director/PDMR Shareholding
01 Nov 2016 10:21 AM
RNS
Total Voting Rights
28 Oct 2016 02:17 PM
RNS
Director/PDMR Shareholding
27 Oct 2016 05:40 PM
RNS
Director/PDMR Shareholding
27 Oct 2016 12:06 PM
RNS
GSK issues new data on shingles candidate vaccine
26 Oct 2016 05:10 PM
RNS
Director/PDMR Shareholding
26 Oct 2016 03:41 PM
RNS
Director/PDMR Shareholding
26 Oct 2016 12:07 PM
RNS
Second Price Monitoring Extn
26 Oct 2016 12:02 PM
RNS
Price Monitoring Extension
26 Oct 2016 12:00 PM
RNS
3rd Quarter Results
25 Oct 2016 02:12 PM
RNS
Director/PDMR Shareholding
24 Oct 2016 07:00 AM
RNS
US FDA submission of shingles candidate vaccine
21 Oct 2016 04:12 PM
RNS
Director/PDMR Shareholding
18 Oct 2016 07:00 AM
RNS
Director/PDMR Shareholding

GSK PLC, known as GSK, is a renowned multinational pharmaceutical and biotechnology company with its global headquarters in London. Traded as GSK on the London Stock Exchange (LSE), it has a rich history that traces back to the establishment of Plough Court Pharmacy in London in 1715. Over the centuries, GSK has grown from a handful of individual founders into a company of over 69,000 people.

The company's journey includes the development of 15 first-in-class or combination vaccines and pioneering medications in respiratory, antibiotics, antivirals, and oncology. GSK has been a leader in medicines that advance the management of asthma and chronic obstructive pulmonary disease (COPD) for 50 years.

In 2000, Glaxo Wellcome and SmithKline Beecham merged to form the modern GSK, becoming a key player on the LSEG. Today, GSK continues to shape the global healthcare landscape, committed to defeating diseases that impact people's health. This evergreen company remains at the forefront of the pharmaceutical industry, embodying its founding principle of improving the quality of human life by enabling people to do more, feel better, and live longer.

GSK share price launched at 346p in 1989. 

UK 100

Latest directors dealings